Review article: the management of side-effects during therapy for hepatitis C

被引：44

作者：

Aspinall, RJ ^{[1
]}

Pockros, PJ ^{[1
]}

机构：

[1] Scripps Clin, Div Gastroenterol Hepatol, La Jolla, CA 92037 USA

来源：

ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2004年 / 20卷 / 09期

关键词：

D O I：

10.1111/j.1365-2036.2004.02192.x

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The results of interferon and ribavirin combination therapy for chronic hepatitis C infection have substantially improved in recent years, such that the majority of patients in randomized-controlled trials now achieve a sustained virological response. However, adverse effects are commonplace, often disabling and may lead to interruption or cessation of therapy with subsequent loss of efficacy. Constitutional, neuropsychiatric and haematological reactions have proved particularly troublesome. In this review, we discuss these adverse effects in more detail and highlight recent advances in their management.

引用

页码：917 / 929

页数：13

共 55 条

[1] Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity [J].

Adinolfi, LE ;

Gambardella, M ;

Andreana, A ;

Tripodi, MF ;

Utili, R ;

Ruggiero, G .

HEPATOLOGY, 2001, 33 (06) :1358-1364

[2] Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study [J].

Afdhal, NH ;

Dieterich, DT ;

Pockros, PJ ;

Schiff, ER ;

Shiffman, ML ;

Sulkowski, MS ;

Wright, T ;

Younossi, Z ;

Goon, BL ;

Tang, KL ;

Bowers, PJ .

GASTROENTEROLOGY, 2004, 126 (05) :1302-1311

[3] Clinical significance of pegylated interferon induced neutropenia: Results from the WIN-R trial [J].

Ahmed, F ;

Jacobson, IM ;

Brown, RS ;

Afdhal, N ;

Rubin, R ;

Spivey, J ;

Freilich, B ;

Regenstein, F ;

Bernstein, D ;

Doig, R ;

Brass, C .

GASTROENTEROLOGY, 2003, 124 (04) :A700-A700

[4]

Azzam H, 2003, HEPATOLOGY, V38, p751A

[5]

Cotler SJ, 2000, J VIRAL HEPATITIS, V7, P211

[6]

Cotler SJ, 2001, AM J GASTROENTEROL, V96, P2730, DOI 10.1111/j.1572-0241.2001.04132.x

[7] Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C [J].

Davis, GL ;

Wong, JB ;

McHutchison, JG ;

Manns, MP ;

Harvey, J ;

Albrecht, J .

HEPATOLOGY, 2003, 38 (03) :645-652

[8] Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C [J].

Davis, GL ;

Esteban-Mur, R ;

Rustgi, V ;

Hoefs, J ;

Gordon, SC ;

Trepo, C ;

Shiffman, ML ;

Zeuzem, S ;

Craxi, A ;

Ling, MH ;

Albrecht, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) :1493-1499

[9] Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage [J].

De Franceschi, L ;

Fattovich, G ;

Turrini, F ;

Ayi, K ;

Brugnara, C ;

Manzato, F ;

Noventa, F ;

Stanzial, AM ;

Solero, P ;

Corrocher, R .

HEPATOLOGY, 2000, 31 (04) :997-1004

[10] Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review [J].

Dieperink, E ;

Willenbring, M ;

Ho, SB .

AMERICAN JOURNAL OF PSYCHIATRY, 2000, 157 (06) :867-876

← 1 2 3 4 5 6 →